Regulators should prohibit health insurers from preventing hospitals and physicians in their networks from directly acquiring and storing drugs used in patient care, according to a white paper released today by AHA.

A number of large health insurers are requiring these providers to accept drugs purchased or handled by their own or affiliated pharmacies, the paper notes. As opposed to the traditional drug acquisition model, 鈥渨hite bagging鈥 policies require hospitals to receive, store, prepare and administer these drugs to patients, while never taking ownership of the drug. As a result, these policies limit the ability of hospital staff to have line of sight into the origin and handling of a drug prior to receipt by the hospital, raising significant concerns and creating substantial challenges.

鈥淭hese actions pose significant risks to quality of care as providers have inadequate control in ensuring patient access to high quality drugs, as well as the appropriate storage and handling of those drugs,鈥 the paper states. 鈥淭hese policies simply serve to drive more revenue to health insurers through their pharmacy benefit management and specialty pharmacy lines of business.鈥

Related News Articles

Headline
A JAMA Internal Medicine study published April 7 examined the effects of changing the default prescription lengths for statins, which are cholesterol-lowering鈥
Headline
The Administration for Strategic Preparedness and Response July 16 announced it will work with the Department of Commerce on an assessment of the active鈥
Headline
The Centers for Medicare & Medicaid Services July 16 released its final guidance on the Medicare Prescription Payment Plan which will begin next year. The鈥
Headline
The Food and Drug Administration yesterday revised its recent guidance for outsourcing facilities compounding certain ibuprofen oral suspension products鈥
Headline
The market for pharmacy benefit manager services is highly concentrated, with commercial insurers often sharing ownership in the PBM, according to an analysis鈥
Headline
The Federal Trade Commission will launch an inquiry into the prescription drug middleman industry, requiring the six largest pharmacy benefit managers to鈥